New Antibody Formats

New Antibody Formats,Volume 369, highlights advances in engineered antibodies, bispecific antibodies, trimerbodies, multispecific mAb-Anticalin formats, lung cancer treatment, immunocytokines, and single domain antibodies.

Format: Hardback
Length: 212 pages
Publication date: 01 June 2022
Publisher: Elsevier Science & Technology

The 369th volume of the International Review of Cell and Molecular Biology serial, titled "New Antibody Formats," showcases groundbreaking advancements in the field. This latest edition presents a captivating collection of engaging chapters on diverse and significant topics, encompassing Current innovative engineered antibodies, Advances in bispecific antibodies, Applications of trimerbodies for cancer immunotherapy, Multispecific mAb-Anticalin formats, New antibody formats to treat Lung Cancer, Immunocytokines: from bench to bedside, and Single domain antibodies in cancer.

Current innovative engineered antibodies:

In recent years, engineered antibodies have emerged as powerful tools in therapeutics and diagnostics. These artificial antibodies, designed to mimic the structure and function of natural antibodies, have shown remarkable promise in targeting various diseases. This chapter explores the latest developments in engineered antibody technology, including the use of novel scaffolds, genetic engineering techniques, and computational approaches to enhance antibody potency, stability, and specificity.

Advances in bispecific antibodies:

Bispecific antibodies are a class of therapeutic agents that bind to two distinct targets simultaneously, enhancing their therapeutic efficacy and reducing side effects. This chapter discusses the latest advancements in bispecific antibody design, including the development of novel scaffolds, fusion proteins, and antibody-drug conjugates. It also highlights the potential applications of bispecific antibodies in the treatment of cancer, autoimmune diseases, and infectious diseases.

Applications of trimerbodies for cancer immunotherapy:

Trimerbodies are a novel class of therapeutic agents that consist of three antibody fragments linked together through non-covalent interactions. These agents have shown promising results in cancer immunotherapy, particularly in targeting solid tumors. This chapter explores the design and development of trimerbodies, their mechanism of action, and their potential applications in the treatment of various types of cancer.

Multispecific mAb-Anticalin formats:

Multispecific antibodies, also known as bispecific or multivalent antibodies, have the potential to target multiple disease-causing proteins simultaneously. This chapter discusses the development of multispecific mAb-Anticalin formats, including the use of antibody fragments, scaffolds, and fusion proteins. It also highlights the potential applications of these agents in the treatment of cancer, autoimmune diseases, and infectious diseases.

New antibody formats to treat Lung Cancer:

Lung cancer is one of the most prevalent and deadly cancers worldwide. This chapter explores the development of new antibody formats specifically designed to target lung cancer cells. It discusses the use of antibody-drug conjugates, bispecific antibodies, and engineered antibodies to enhance the treatment of lung cancer and improve patient outcomes.

Immunocytokines: from bench to bedside:

Immunocytokines are a class of therapeutic agents that combine the properties of antibodies and cytokines to target and kill cancer cells. This chapter discusses the development of immunocytokines, their mechanism of action, and their potential applications in the treatment of various types of cancer. It also highlights the challenges and limitations associated with the use of immunocytokines and the ongoing efforts to improve their efficacy and safety.

Single domain antibodies in cancer:

Single domain antibodies, also known as nanobodies, are a novel class of therapeutic agents that possess unique properties and characteristics. This chapter discusses the development of single domain antibodies, their mechanism of action, and their potential applications in the treatment of cancer. It also highlights the challenges and limitations associated with the use of single domain antibodies and the ongoing efforts to improve their efficacy and stability.

In conclusion, the 369th volume of the International Review of Cell and Molecular Biology serial, titled "New Antibody Formats," presents a comprehensive and up-to-date overview of the latest advancements in the field of antibody therapy. The chapters in this volume cover a wide range of topics, from innovative engineered antibodies to bispecific antibodies, trimerbodies, multispecific mAb-Anticalin formats, new antibody formats to treat lung cancer, immunocytokines, and single domain antibodies in cancer. These chapters provide valuable insights into the potential applications of antibody therapy in various diseases and highlight the ongoing efforts to improve the efficacy and safety of these agents. As the field of antibody therapy continues to evolve, researchers and clinicians will undoubtedly find new and innovative ways to leverage the power of antibodies to treat and cure diseases.

Dimension: 229 x 152 (mm)
ISBN-13: 9780323994026